Findings on use of acute and preventive migraine therapy continue to reveal gaps with far more patients eligible than the proportions using either type.
Lifetime consultation for migraine headache in primary care was common (70.03%), according to the first published findings of the longitudinal multicohort OVERCOME study.
And yet the study also found that the proportions of patients with migraine who are eligible for both acute and preventive treatment are far greater than those using the treatments; in fact, the study found that even lifetime use of migraine-specific and widely available triptans is currently only 22.7%.
Led by well known migraine expert and investigator Richard Lipton, MD, of the department of neurology at the Albert Einstein College of Medicine in New York, OVERCOME is monitoring changes in patterns of consultation, diagnosis, and acute and preventive treatment for migraine to help identify unmet needs in care and inform treatment decisions.
The findings summarized in the slide show below highlight cross-sectional data for the first cohort in the multicohort study.